Vardenafil hydrochloride trihydrate CAS: 224785-90-4 White powder
1. Product title: Vardenafil
2. Pictures of the product:
|Appearance||White crystalline or crystalline powder||Main Effect||
|Brand Name||Kan Ying||Store-method||Cool Dry Place|
|Shelf Life||2 Years When
3. Product Description:
Vardenafil is a PDE5 inhibitor that acts on erectile dysfunction. Quick onset time, within 15 to 30 minutes. Side effects are small, but depending on individual differences, less than 2% of people will experience a mild headache. Soluble in water and ethanol, it is the ideal raw material for making aphrodisiac wine, soft capsule and oral liquid, lasting more than 6 hours.
The recommended starting dose is 10mg, taken approximately 25 to 60 minutes before intercourse. In clinical trials, when taken four to five hours before intercourse, it still shows efficacy. The maximum recommended frequency of use is once a day. Vardenafil can be taken with food or alone. Sexual stimulation is needed as an instinctive response to treatment.
The dose can be increased to 20mg or reduced to 5mg depending on efficacy and tolerability. The maximum recommended dose is 20mg per day.
Patients with mild liver damage (Child-pughA) do not need to adjust the dose; For child-pughb patients, the recommended initial dose is 5mg due to reduced clearance of vardenafil and is gradually increased to 10mg depending on tolerability and efficacy; The pharmacokinetics of vardenafil in patients with severe liver damage (child-pughC) have not been studied.
Dose adjustment was not required in patients with mild, moderate, or severe renal impairment. Pharmacokinetics studies of vardenafil in dialysis patients have not been conducted.
7 Adverse reactions
Vardenafil was well tolerated in more than 7,800 patients in global clinical trials. Adverse events that occur are usually transient, mild to moderate.
Placebo controlled clinical trials:
The following adverse events have been reported in placebo-controlled clinical trials at the recommended dose of vardenafil:
The incidence of adverse reactions in the vardenafil group at 5mg, 10mg and 20mg was higher than that in the placebo group, and the incidence was more than 1% :
The whole body:
Adverse reactions, headache; Vardenafil, 10.5%; Placebo, 2.1 percent.
Adverse reactions, facial flushing; Vardenafil, 11.6%; Placebo, 0.9%.
① Adverse reactions, dyspepsia; Vardenafil, 2.7%; Placebo, < 0.1%. ② Adverse reactions, nausea; Vardenafil, 1.2%; Placebo, 0.2%.
Adverse reactions, vertigo; Vardenafil, 1.8%; Placebo, 0.4%.
Adverse reactions, rhinitis; Vardenafil, 4.4%; Placebo, 0.3%.
8. Pictures of the product: